Gilead eyes takeover of cancer biotech Tizona, despite its t...

Gilead Sciences’ run of oncology-focused deals has continued with an option to buy cancer immunotherapy specialist Tizona – even though the biotech’s lead drug candidate is alr

J&J's Tremfya to join crowded psoriatic arthritis market aft...

The FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 class to gain a foothold in this indication. 

After Celgene deal, BMS shoots up pharma market cap rankings

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat

AbbVie forges $3.9 billion oncology alliance with Genmab

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgk

Saunders steps aside as AbbVie closes in on Allergan merger

AbbVie, J&J embed Imbruvica deeper in CLL therapy with new a...